In an update on the European Medicines Agency's website on Wednesday, the regulator said that the approval for AstraZeneca's Vaxzevria had been withdrawn “at the request of the marketing authorisation holder.”Within weeks, however, concerns grew about the vaccine's safety, when dozens of countries suspended the vaccine's use after unusual but rare blood clots were detected in a small number of immunised people.
Partial results from its first major trial — which Britain used to authorise the vaccine — were clouded by a manufacturing mistake that researchers didn’t immediately acknowledge.Insufficient data about how well the vaccine protected older people led some countries to initially restrict its use to younger populations before reversing course.